查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球輸血診斷市場
市場調查報告書
商品編碼
1153814

2022-2029 年全球輸血診斷市場

Global Transfusion Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

輸血診斷市場預計2021年將達到39.5529億美元，2029年將達到67.0735億美元，在預測期內（2022-2029年）以9.68%的複合年增長率增長。

輸血是將血液輸送到體內。輸血用於各種醫療條件，以替代丟失的血液成分。輸血可替代手術期間或因嚴重受傷而流失的血液。當身體因血癌等疾病而無法正常生產血液時，也可以使用輸血。

市場動態

血癌、重傷和事故的發病率不斷增加，增加了對這些診斷的需求。手術數量的增加、研發支出的增加以及新產品發布的增加預計將推動市場增長。

新產品發布的增加、嚴重傷害和事故案例的增加是市場增長的驅動力。

由於血癌、貧血、鐮狀細胞性貧血、腎病等慢性病和輸血感染等嚴重感染的增加，醫療行業對診斷的需求推動了全球輸血診斷市場的發展.被拖走。越來越多的事故和傷害以及痛苦的手術將推動市場增長。例如，2022 年 8 月，QuidelOrtho Corporation 宣布其子公司體外診斷服務提供商 Ortho Clinical 開發的 Ortho 工作站獲得了 AABB“符合標準”指定質量印章。該工作站是集培養箱和離心機於一體的二合一血液檢測系統。

各種資金來源、新技術進步以及越來越多的最新創新產品發布導致對這些輸血診斷的高需求。例如，2022 年 7 月，羅氏推出了 Elecsys HCV Duo 免疫分析，這是第一個能夠從單個人體樣本中獨立檢測丙型肝炎病毒抗體和抗原狀態的免疫分析。該測試可以及早發現感染，可用於正在康復或出現慢性感染症狀的患者。

與輸血診斷相關的高成本阻礙了市場增長。

然而，用於輸血診斷的有質量保證的試劑盒和儀器的高成本是限制增長的主要因素。缺乏經驗豐富的專業人員使得很難使用自動化設備並提供準確的結果。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了負面影響。 COVID-19 的爆發嚴重影響了醫療保健行業。由於所有獻血都停止，輸血診斷市場因 COVID 遭受了巨大損失。由於 COVID 和輸血感染的傳播，人們拒絕輸血。但現在，市場進入者正在改變他們的長期和短期增長戰略，利用研究市場和創造尖端項目來對抗這一流行病。世界各地正在發生各種舉措、合作和合併，推動了市場的增長。例如，2022 年 8 月，體外診斷創新技術提供商 QuidelOrtho Corp 宣布加入聯盟，該聯盟是血液和生物治療促進協會成立的聯盟，旨在加強血液供應。

內容

第 1 章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 新產品發布次數增加
      • 對輸血診斷試劑的需求增加
    • 約束因素
      • 與輸血診斷設備相關的高成本
    • 機會
    • 影響分析

第五章行業分析

  • 搬運工的五種力量
  • 未滿足的需求
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 設備/套件
  • 試劑
  • 其他

第8章按輸血類型

  • 紅細胞輸注
  • 血小板輸注
  • 血漿輸注
  • 全血輸血

第 9 章按應用

  • 疾病篩查
  • 血型測試
  • 其他

第 10 章最終用戶

  • 血庫
  • 醫院
  • 實驗室
  • 血漿分離設施
  • 其他

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • Ortho Clinical Diagnostics
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Beckman Coulter
  • Quotient Limited
  • Abbott Laboratories
  • Diagast
  • Becton, Dickinson & Company
  • Immucor Inc.
  • Grifols S.A.
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche Ltd.

第14章 全球輸血診斷市場-DataM

簡介目錄
Product Code: DMMDP858

Market Overview

Transfusion Diagnostics Market was valued at US$ 3,955.29 million in 2021 and is estimated to reach US$ 6,707.35 million by 2029, growing at a CAGR of 9.68% during the forecast period (2022-2029).

Blood transfusion is the process of transferring blood to the body. Transfusions are used for various medical conditions to replace lost blood components. Blood transfusions replace blood lost during surgery or due to a severe injury. A transfusion also may be done if the body can't make blood properly because of an illness such as blood cancer.

Market Dynamics

The increasing demand for these diagnostic products is due to the rising incidence of blood cancer, serious injuries, and accidents. The rising number of surgeries, increasing research and development expenditure and growth in novel product launches are expected to drive market growth.

The increasing novel product launches and rising number of serious injuries and accident cases will drive market growth.

The global market for transfusion diagnostics is primarily driven by the healthcare industry's demand for diagnostic products due to increasing chronic illnesses, including blood cancer, anemia, sickle cell anemia, kidney disease and serious infection such as transfusion-transmitted infections. The rising number of accidents, trauma and painful surgeries drive the market's growth. For instance, in Aug 2022, QuidelOrtho Corporation announced receiving AABB "standards compliant" designation quality seal for an Ortho workstation developed by its subsidiary, Ortho Clinical, in vitro diagnostic services provider. This workstation is a blood testing system that has a 2-in-1 feature as it combines an incubator and a centrifuge.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these transfusion diagnostics. For instance, in July 2022, Roche launched Elecsys HCV Duo immunoassay, the first immunoassay that permits independent detection of hepatitis C virus antibodies and antigen status by a single human sample. This test can detect the infection at an early stage and can be used during the patient's recovery phase or when showing chronic infection symptoms.

The high costs associated with transfusion diagnostics will hamper the market's growth.

However, high rates of quality-assured kits and instruments for transfusion diagnostics are the major factor restraining the growth. The unavailability of experienced professionals makes it difficult to handle the automated instruments and provide accurate results.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transfusion diagnostics market has experienced huge losses due to COVID, as all the blood drives were canceled. People refused to get transfusions because of the spread of COVID and transfusion-transmitted infections. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, QuidelOrtho Corp, in vitro diagnostic innovative technology provider, announced joining the Alliance, a coalition established by the Association for Advancement of Blood and Biotherapies to strengthen the blood supply.

Segment Analysis

The disease screening segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The disease screening segment is the highest market holder in the global transfusion diagnostics market. All the blood donated is screened to get evidence of the absence of any infection in the blood before releasing the blood and its components for clinical use, which is known as disease screening. Introducing serological assays that target virus-specific antigens and antibodies is very useful for detecting infection in donated blood, such as transfusion-transmitted infectious agents like TTIs, HIV, hepatitis B virus and hepatitis C virus. The latest nucleic acid amplification technology screening effectively minimizes the risk of infection.

Disease screening dominates the market due to increased blood cancer cases globally. According to the World Health Organization, in 2022, approximately 1.24 million blood cancer cases occur globally annually. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For Instance, in Jun 2022, Grifols, plasma-derived therapy and innovative diagnostic solutions developer, announced receiving the CE mark for Procleix Plasmodium Assay, 1st automatic nucleic acid test system specially designed for blood donors for patients related to malaria.

Geographical Analysis

North America region holds the largest market share of the global transfusion diagnostics market.

North America dominates the global transfusion diagnostics market, primarily attributed to the rising prevalence of chronic ailments such as blood cancer, anemia, hemophilia, kidney disease and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the World Health Organization, in 2022, more than 2 million people will suffer from anemia globally, affecting around 25% of the world's population.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Sep 2022, Grifols, a plasma medicine manufacturer, announced its agreement with Canada's national blood authority, Canadian Blood Services, to expand its self-sufficiency in essential plasma protein therapies and immunoglobulin medicines.

Competitive Landscape

The transfusion diagnostics market is highly competitive with local and global companies' presence. Ortho Clinical Diagnostics, Beckman Coulter, Quotient Limited, Abbott Laboratories, Diagast, Becton, Dickinson & Company, Immucor Inc., Grifols S.A., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, Quidel Corporation announced transaction completion to combine with Ortho Clinical Diagnostics Holdings to form QuidelOrtho Corporation, in vitro diagnostic products and services provider company.

Ortho Clinical Diagnostics:

Overview:

Ortho Clinical Diagnostics is a company that provides in vitro diagnostic equipment for blood typing. It produces automated and semiautomated testing products and testing menu products. It was established in 1939 and is headquartered in New Jersey, United States.

Product Portfolio:

Ortho Vision Platform: This platform comprises analyzers that test the compatibility of blood to make sure that patients receive the correct blood type during transfusion. Ortho vision products are designed for high-volume labs, allowing complex immunohematology testing, including serial dilutions, identifying particular cell antibodies and reflex tests.

Key Development: In Sep 2021, Ortho Clinical Diagnostics, an in vitro diagnostic company, announced the launch of Immediate Spin Crossmatch (ISXM) that will provide aid in determining the incompatibility during blood transfusion between the recipients and donors. This serological test determines the incompatibility of ABO blood type between the recipient plasma and donor RBCs.

The global transfusion diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing demand for diagnostic transfusion products
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with diagnostic transfusion instruments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments & Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Reagents
  • 7.4. Others

8. By Transfusion Types

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 8.1.2. Market Attractiveness Index, By Transfusion Types
  • 8.2. Red Blood Cell Transfusion *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Platelet Transfusion
  • 8.4. Plasma Transfusion
  • 8.5. Whole Blood Transfusion

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Disease Screening *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Blood Typing
  • 9.4. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Blood Banks*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Hospitals
  • 10.4. Laboratories
  • 10.5. Plasma Fractionation Facilities
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Ortho Clinical Diagnostics
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Beckman Coulter
  • 13.3. Quotient Limited
  • 13.4. Abbott Laboratories
  • 13.5. Diagast
  • 13.6. Becton, Dickinson & Company
  • 13.7. Immucor Inc.
  • 13.8. Grifols S.A.
  • 13.9. Bio-Rad Laboratories
  • 13.10. F. Hoffmann-La Roche Ltd.

LIST NOT EXHAUSTIVE

14. Global Transfusion Diagnostics Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us